Several studies have identified MAL2 amplification and/or overexpression in breast cancer [6–9] and in other cancer types including primary ovarian carcinoma [10–12], pancreatic carcinoma [13, 14], prostate adenocarcinoma [15], oral squamous cell carcinoma [16] and head and neck squamous cell carcinoma [17]. This evidence concerns the gene MAL2 and breast carcinoma.